live attenuated SARS-CoV-2 virus vaccine (recombinant measles virus vector) (Zydus-Cadila)

N/A

Report date: 2025/01/26 18:01:30

Base Information

Drug Namelive attenuated SARS-CoV-2 virus vaccine (recombinant measles virus vector) (Zydus-Cadila)

Drug Alias Namerecombinant measles virus vector vaccine (live attenuated) (Zydus-Cadila)

ClassificationVaccines > Development/production technology > Live attenuated vaccineVaccines > Development/production technology > Recombinant vector vaccineVaccines > Application > Prophylactic vaccine

Mechanisms of ActionImmunomodulators

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIndia

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesZydus Cadila

China Registration ClassN/A

Develop Information

Active CompaniesZydus Cadila

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A